Local and national advocacy support.
Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.
Midwest Immunology Clinic, Plymouth, MN, USA.
Ralph S
RS
Shapiro
Marcia
M
Boyle
Elena E
EE
Perez
D003659:Decision Making, Organizational; D006297:Health Services Accessibility; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy / Q000191:economics*; D010344:Patient Advocacy / Q000191:economics* / Q000331:legislation & jurisprudence; D057240:Patient Preference / Q000191:economics / Q000331:legislation & jurisprudence*; D057285:Precision Medicine
D016756:Immunoglobulins, Intravenous